The presence of TP53 alteration in itself is an adverse prognostic marker in any malignancy (58) and long term PDA survivors have consistently demonstrated absence of KRAS and TP53 mutations (59, 60). The gene discussed is KRAS; the disease is Patent ductus arteriosus.